Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Windlas Biotech Ltd Performance

Today's Low
499.20
arrowIcon
Today's High
517.75
52 Wk Low
260.10
arrowIcon
52 Wk High
590.85


Open

504

Traded Value (Cr)

44.87 L

Prev. Close

504.2

VWAP

512.11

Volume

46,309

Face Value

5

Windlas Biotech Ltd Fundamentals

Market Cap
₹ 1,079 Cr
P/E Ratio (TTM)
20.50
P/B Ratio
2.59
Debt to Equity
0.02
ROE
11.23 %
EPS (TTM)
25.31
Dividend Yield
0.78%
Book Value
200.09

Click here to know more about Fundamentals

Windlas Biotech Ltd Financials

Windlas Biotech Ltd Financials

Windlas Biotech Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 62.82 % 62.82 % 62.82 % 62.82 %
Retail 21.19 % 21.21 % 21.63 % 22.02 %
Mutual Funds 10.37 % 10.40 % 10.43 % 10.51 %
Others 4.45 % 4.22 % 4.32 % 3.86 %
FII 1.18 % 1.35 % 0.80 % 0.80 %

Promoters

62.82%

Retail

21.19%

Mutual Funds

10.37%

Others

4.45%

FII

1.18%

Promoters

62.82%

Retail

21.21%

Mutual Funds

10.40%

Others

4.22%

FII

1.35%

Promoters

62.82%

Retail

21.63%

Mutual Funds

10.43%

Others

4.32%

FII

0.80%

Promoters

62.82%

Retail

22.02%

Mutual Funds

10.51%

Others

3.86%

FII

0.80%

Resistance and Support

₹523.47

PIVOT

resistance-arrow
Resistance
First Resistance₹534.833
Second Resistance₹548.217
Third Resistance₹559.583
support-arrow
Support
First Resistance₹510.083
Second Resistance₹498.717
Third Resistance₹485.333
RSI45.023
MACD-6.143
ADX18.489
CCI-167.182

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day46,30925,53555.14
Week48,44225,75452.99
1 Month55,04829,62555.92
6 Months21,90211,31851.68

About Windlas Biotech Ltd

Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. The company has state-of-the-art manufacturing plant facilities located in Dehradun, Uttarakhand, India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. Moreover, the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders. The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.

Managing Director

Hitesh Windlass

Founded

2001

NSE Symbol

WINDLAS

Windlas Biotech Ltd Management

NameDesignation
Vivek DhariwalChairman & Independent Directo
Ashok Kumar WindlassWhole-time Director
Hitesh WindlassManaging Director
Manoj Kumar WindlassJoint Managing Director
Pawan Kumar SharmaExecutive Director
Prachi Jain WindlassNon-Exec & Non-Independent Dir
Srinivasan VenkataramanNon-Exec. & Independent Dir.
Gaurav GulatiNon-Exec. & Independent Dir.
Ananta Narayan PandaCompany Sec. & Compli. Officer

Windlas Biotech Ltd News

Windlas Biotech commissions its injectable facility
Windlas Biotech consolidated net profit rises 64.31% in the December 2023 quarter
Sales rise 35.51% to Rs 162.21 crore
Windlas Biotech schedules board meeting
On 8 February 2024
Windlas Biotech consolidated net profit rises 15.09% in the September 2023 quarter
Sales rise 15.02% to Rs 152.67 crore
Windlas Biotech to conduct board meeting
On 8 November 2023
Windlas Biotech to conduct AGM
On 12 September 2023
Windlas Biotech fixes record date for final dividend
Record date is 05 September 2023
Windlas Biotech consolidated net profit rises 23.16% in the June 2023 quarter
Sales rise 20.72% to Rs 144.79 crore
Windlas Biotech announces board meeting date
On 8 August 2023
Windlas Biotech to declare Quarterly Result
On 8 August 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,616 Cr
₹ 1,512.15
(1.17 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,369.20
(0.77 %)
33.36
DIVISLAB₹ 1,00,611 Cr
₹ 3,822.40
(0.86 %)
73.75
DRREDDY₹ 98,044 Cr
₹ 5,891.25
(0.24 %)
22.59
ZYDUSLIFE₹ 97,423 Cr
₹ 983.05
(1.53 %)
36.23

Windlas Biotech Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Windlas Biotech Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Windlas Biotech Ltd's share price is ₹511.50 as of May 10, 2024

Windlas Biotech Ltd's P/E ratio is 20.50 times as of May 10, 2024.

Windlas Biotech Ltd's most recent financial reports indicate a price-to-book ratio of 2.59, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Windlas Biotech Ltd's market is 1,079 Cr as on May 10, 2024.

The current financial records of Windlas Biotech Ltd show a 11.23% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Windlas Biotech Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Windlas Biotech Ltd's 52-week high and low as of May 10, 2024 are ₹517.75 and ₹499.2 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Windlas Biotech Ltd stands at 62.82%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 1.35% to 1.18%.